Axa
MRNA icon

Axa’s Moderna MRNA Stock Holding History

Axa’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$477K Sell
7,790
-36
-0.5% -$1.86K 0.52% 31
2026
Q1 		$398K Sell
7,826
-3,079
-28% -$144K 0.16% 64
2025
Q4 		$322K Buy
+10,905
New +$296K 0.15% 67
2025
Q3 		– Sell
-48,000
Closed -$1.32M – 682
2025
Q2 		$1.32M Sell
48,000
-119,024
-71% -$3.13M ﹤0.01% 837
2025
Q1 		$4.74M Sell
167,024
-2,158
-1% -$76.6K 0.02% 557
2024
Q4 		$7.03M Sell
169,182
-38,456
-19% -$1.84M 0.02% 455
2024
Q3 		$13.9M Buy
207,638
+2,649
+1% +$243K 0.04% 344
2024
Q2 		$24.3M Buy
204,989
+1,947
+1% +$246K 0.07% 238
2024
Q1 		$21.6M Sell
203,042
-271,510
-57% -$27.4M 0.06% 264
2023
Q4 		$47.2M Sell
474,552
-128,488
-21% -$10.8M 0.15% 148
2023
Q3 		$62.3M Buy
603,040
+109,999
+22% +$12.3M 0.22% 109
2023
Q2 		$59.9M Buy
493,041
+113,540
+30% +$15.1M 0.2% 118
2023
Q1 		$58.3M Sell
379,501
-147,412
-28% -$24.3M 0.2% 126
2022
Q4 		$94.6M Buy
526,913
+291,235
+124% +$47.6M 0.34% 74
2022
Q3 		$27.9M Buy
235,678
+110,303
+88% +$16.7M 0.11% 211
2022
Q2 		$17.9M Sell
125,375
-2,224
-2% -$318K 0.07% 318
2022
Q1 		$22M Buy
127,599
+34,472
+37% +$5.8M 0.06% 343
2021
Q4 		$23.7M Sell
93,127
-37,470
-29% -$11M 0.06% 330
2021
Q3 		$50.3M Sell
130,597
-22,023
-14% -$8.12M 0.14% 180
2021
Q2 		$35.9M Sell
152,620
-17,418
-10% -$3.11M 0.1% 233
2021
Q1 		$22.3M Buy
170,038
+3,160
+2% +$458K 0.07% 327
2020
Q4 		$17.4M Buy
166,878
+3,790
+2% +$383K 0.05% 363
2020
Q3 		$11.5M Buy
163,088
+1,513
+0.9% +$105K 0.04% 410
2020
Q2 		$10.4M Buy
161,575
+3,181
+2% +$174K 0.04% 419
2020
Q1 		$4.74M Buy
+158,394
New +$3.64M 0.02% 530

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Axa's MRNA Position: Q2 2026 in Review

Axa reduced its Moderna (MRNA) stake by 0.46% in Q2 2026, selling an estimated $1.86K and leaving 7,790 shares worth $477K. The position accounts for 0.52% of the portfolio, ranked #31.

Axa first reported a position in MRNA in Q1 2020 and has held it in 25 quarters since. The position peaked at $94.6M in Q4 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Axa held 7,790 shares of Moderna worth $477K as of Q2 2026.
  • Axa sold 36 Moderna shares in Q2 2026, an estimated $1.86K.
  • Moderna made up 0.52% of Axa's portfolio in Q2 2026, its #31 holding.
  • Axa first reported a position in Moderna in Q1 2020 and has held it in 25 quarters since.
  • Axa's Moderna position peaked at $94.6M in Q4 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Axa's 13F filing for Q2 2026, filed 14 Aug 2026.